An Exploration of Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer

Sponsor
Changzhou Cancer Hospital of Soochow University
Study ID
NCT03129256
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This study is to explore the potential efficacy and safety of low-dose Apatinib combined with S-1 in patients with advanced lung cancer. Patients with advanced NSCLC will be treated with oral apatinib and S-1 after treatment failure of standard regimen.

Key Dates

Start date
Dec 1, 2016
Status verified
Dec 2019
Primary completion
Dec 30, 2018
Completion
Dec 30, 2018

Study Design

Enrollment
52 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib & S-1
    Apatinib Mesylate tablet combined with S-1 Capsules Apatinib Mesylate tablet 250mg once daily combined with S-1(Tegafur,Gimeracil and Oteracil Potassium Capsules) 40mg\~60mg twice daily by mouth, d1-14, repeated every 3 weeks.

Primary Outcome Measure

Progression Free Survival(PFS) [ Time Frame: 2 years ]

Related Studies